TABLE 1.

Round 1 Sample Clinical and Demographic Characteristics

Clinical/Demographic Characteristic	Adult Patients (N = 16), n (%)	Adolescent Patients (N = 8), n (%)	Total (N = 24), n (%)
Sex
Male	8 (50%)	4 (50%)	12 (50%)
Female	8 (50%)	4 (50%)	12 (50%)
Age, years
Mean (median) [range]	50.3 (51.5) [27.0–75.0]	15.6 (15.5) [14.0–17.0]	38.7(45.5) [14.0–75.0]
Ethnicity
Caucasian or white	11 (69%)	5 (63%)	16 (67%)
Black or African American	3 (19%)	1 (13%)	4 (17%)
Hispanic	2 (13%)	2 (25%)	4 (17%)
Education (highest level completed)
High school diploma or equivalent	5 (31%)*	—	—
College or associate’s degree	5 (31%)	—	—
Bachelor’s degree	4 (25%)	—	—
Graduate degree	1 (6%)	—	—
Other	1 (6%)	—	—
Time since diagnosis, years
Mean (median) [range]	10.1 (10.6) [1.0−23.7]	2.8 (1.4) [1.0−7.7]	7.6 (7.0) [1.0−23.7]
Disease severity (reported by referring clinicians)
Mild	2 (13%)	4 (50%)	6 (25%)
Moderate	13 (81%)	3 (38%)	16 (67%)
Severe	1 (6%)	1 (13%)	2 (8%)
Comorbidities
High blood pressure	3 (19%)	0 (0%)	3 (13%)
Diabetes mellitus	1 (6%)	0 (0%)	1 (4%)
Treatment (current)†
Adalimumab (HUMIRA, AbbVie, North Chicago, IL)	8 (50%)	2 (25%)	10 (42%)
Vedolizumab (ENTYVIO, Takeda US, Deerfield, IL)	3 (19%)	0 (0%)	3 (13%)
Infliximab (REMICADE, Janssen, Titusville, NJ)	2 (13%)	2 (25%)	4 (17%)
Prednisone/corticosteroids‡	2 (13%)	0 (0%)	2 (8%)
No treatment (including modified diet/probiotics)	2 (13%)	4 (50%)	6 (25%)
Time on biologic treatment, mean [range]	N = 13, 4.4 [0.3–16.9]	N = 4, 0.8 [0.2–2.3]	—
Time since diagnosis years, mean [range]	11.5 [1–17.25]	1.43 [1.08–2.3]	—

*n = 1 completed some college.

^†Other treatments: n = 1 ciprofloxacin every 5 days and Imodium A-D as required, n = 1 azathioprine (IMURAN, Aspen Pharma Trading Ltd, Dublin, Ireland) 5 mg/day.

^‡Patients prescribed corticosteroids also received Adalimumab (HUMIRA^®, AbbVie, North Chicago, Illinois).